Enlitic Announces Capital Raise Featuring Conditional Placement, Security Purchase Plan, and Convertible Note Conversion

Dual-Component Capital Raise: Conditional Placement and Security Purchase Plan

Enlitic’s capital raising consists of two simultaneous components. The first is a conditional placement of new CDIs, representing common stock shares of the Delaware-incorporated company, aimed at eligible institutional, sophisticated, or professional investors. The second component is a security purchase plan available to eligible existing CDI holders. Collectively, these are referred to as "the Offer."

Eligibility to participate in the Offer is subject to legal requirements and the discretion of Enlitic and its bookrunner, meaning not all registered investors will qualify for the placement tranche. The exact pricing and quantity of CDIs to be issued under each component were not disclosed in the 3 July 2026 investor presentation or announcement.

Convertible Note Conversion Integrated into Capital Restructuring

In addition to the equity raise, the transaction includes a convertible note conversion, enabling Enlitic to restructure existing debt by converting outstanding convertible notes into new CDIs or common stock. This approach helps reduce debt while raising fresh equity capital.

Details such as the conversion price, face value of notes converted, and resulting CDI issuance were not provided in the investor presentation or announcement. Investors will need to await further disclosures, including shareholder meeting materials, to assess the dilutive effects of the conversion.

Shareholder Approval Essential for Placement and Share Authorisation Increase

Shareholder approval is a key condition for the Offer’s completion. Although Enlitic is incorporated in Delaware, it remains subject to ASX Listing Rules and CHESS depositary interest arrangements for its Australian listing. Approval is required not only for the conditional placement, including any director participation, but also for amending the Certificate of Incorporation to increase authorised shares.

This requirement introduces execution risk, as the Offer cannot proceed until shareholders approve both elements. The company has not disclosed the date of the shareholder meeting, record date, or voting thresholds. Investors should track ASX disclosures for the formal meeting notice.

Barrenjoey Markets Leads Placement as Manager and Bookrunner

Enlitic has engaged Barrenjoey Markets Pty Limited (ABN 66 636 976 059), a leading Australian independent investment bank, as lead manager and bookrunner for the conditional placement. Barrenjoey will manage investor demand and allocation during the institutional bookbuild process.

The company clarified that Barrenjoey has not authorised or been involved in preparing or distributing the investor presentation, consistent with standard legal protocols. Fee arrangements with Barrenjoey were not disclosed.

Non-Underwritten Offer Poses Capital Raising Risks

The Offer is explicitly not underwritten, meaning there is no guarantee that Enlitic will raise the full targeted capital. Insufficient demand during the bookbuild or undersubscription of the SPP could result in a lower raise, impacting the company’s funding and operational runway.

Without underwriting, Enlitic assumes the risk of a partial raise, lacking a backstop commitment from the lead manager. Nonetheless, the company and advisers appear confident in investor interest, though outcomes depend on market conditions at launch.

Security Purchase Plan Details Pending for Eligible CDI Holders

The SPP will offer eligible existing CDI holders an opportunity to subscribe for additional securities at the placement price, typically up to a capped amount per holder, without requiring a full prospectus. However, specifics such as issue price, subscription limits, offer period, and record date have yet to be disclosed.

Investors should anticipate a forthcoming SPP booklet or offer document from Enlitic in the coming weeks for these details.

Delaware Incorporation Implications for Australian CDI Holders

Enlitic is incorporated in Delaware and trades on the ASX via CHESS depositary interests, which represent economic interests in the company’s common stock. This dual jurisdiction subjects Enlitic to both US corporate law and ASX Listing Rules.

The required amendment to increase authorised shares must comply with Delaware law as well as ASX requirements. Australian CDI holders’ rights may differ from holders of ordinary shares in Australian companies, and investors are advised to seek independent legal and financial advice before investing.

Risks Highlighted in Investor Presentation

The investor presentation includes a "Key Risks" section advising prospective investors to consider risks such as shareholder dilution, uncertainty of proceeds use, ongoing funding needs, and the possibility that shareholder approval may not be granted.

The presentation is summary in nature, not a prospectus or product disclosure statement, and has not been lodged with ASIC or other regulators. Investors are urged to conduct independent due diligence and seek professional advice before acting on the information provided.

Capital Raise Supports Enlitic’s AI Medical Imaging Growth Strategy

Enlitic develops AI-assisted medical imaging software to aid radiologists and healthcare providers in image interpretation. Capital raising is typical for growth-stage technology companies in capital-intensive healthcare sectors requiring sustained investment for product development, regulatory approval, commercialization, and customer acquisition.

Though the use of proceeds was not disclosed, the inclusion of convertible note conversion alongside new equity suggests Enlitic aims to address existing obligations while securing funds for its next operational phase. Key upcoming milestones include shareholder meeting materials, SPP terms, bookbuild results, and management updates on capital deployment aligned with the company’s AI medical imaging strategy.

Next Steps and Timeline for Enlitic’s Capital Raising

Following the 3 July 2026 investor presentation, the immediate next steps are completing the institutional bookbuild for the conditional placement and releasing SPP documentation to eligible CDI holders. Subsequently, a shareholder meeting will be convened to approve the placement and authorised share increase.

No specific timetable has been disclosed. The Offer remains conditional until shareholder approval is obtained, and CDIs issued under the placement will not be freely tradable until then. The share price impact is currently unclear. Investors should monitor Enlitic’s continuous disclosure updates on the ASX website for further information as the transaction progresses.